BioClarus Insights

The Medicine We Hope Not to Need

Original research published

Conceptual still life of an unlabelled medicine vial in a glass cabinet with a hospital corridor beyond

New antibiotics illustrate a fundamental tension in biotech valuation: medicines held in reserve for treatment failure have genuine clinical value that conventional sales forecasts struggle to quantify. The World Health Organization's June 2024 assessment identified gaps in both the number and innovation level of antibacterial candidates relative to priority drug-resistant bacteria—a snapshot assessment rather than current pipeline description. Distinguishing ten different programs requires examining whether they address distinct organisms, resistance patterns, or patient populations, not merely counting their existence. Low usage volume can reflect careful prescribing and successful preparedness rather than failure. The NHS England antimicrobial subscription model exemplifies an alternative: fixed annual fees based on health system value rather than units sold, separating reward from volume expectations and creating space to recognize availability as part of value. This approach succeeds only through rigorous product selection, contribution evaluation, reliable supply, and appropriate prescribing practices. Evidence frameworks must address both treatment role and preparedness role. The enduring challenge lies in supporting innovation while keeping appropriate use central, recognizing that diagnostics, clinical expertise, supply planning, and prescribing practices all determine what a discovery can accomplish. Executive implication: organizations evaluating antibiotic value should examine whether evidence demonstrates right-patient access and whether funding mechanisms support both availability and appropriate use, rather than relying on volume sold as a proxy for success.

Read the full Clarus Biotech Review article

Sources

  1. www.who.int/news/item/14-06-2024-who-releases-report-on-state-of-development-of-antibacterials
  2. www.england.nhs.uk/publication/antimicrobial-products-subscription-model-guidance-on-commercial-arrangements/

Deep Domain Expertise Across Therapeutic Areas